Eosinophilic asthma is not a rare disease. It is actually the most common subtype of severe asthma, estimated to account for about 50% of all severe asthma cases worldwide. With roughly 300 million people living with asthma globally and 5 to 10% of those cases classified as severe, eosinophilic asthma affects millions of people, far exceeding the threshold for a rare disease designation.
How Common It Actually Is
In the United States, a disease is considered “rare” if it affects fewer than 200,000 people. Eosinophilic asthma blows past that number. Asthma overall affects tens of millions of Americans, and severe asthma makes up 5 to 10% of those cases. Since eosinophilic asthma represents roughly half of severe asthma, that puts the affected population well into the millions in the U.S. alone.
That said, the exact prevalence is still considered uncertain. One reason is that eosinophilic asthma requires specific testing to identify, and not every person with asthma gets that testing. Many people with this subtype go unrecognized for years, which can create the impression that it’s less common than it really is. The condition is underdiagnosed rather than uncommon.
What Makes It a Distinct Subtype
Eosinophilic asthma is defined by high levels of eosinophils, a type of white blood cell that drives inflammation in the airways. In most forms of asthma, the immune system overreacts to triggers like allergens or irritants. In eosinophilic asthma specifically, the body produces a signaling molecule called IL-5 in excessive amounts. IL-5 is the primary driver behind eosinophil growth, activation, and migration into the lungs, where they cause swelling, mucus production, and airway narrowing.
This process can be triggered by inhaled allergens, but it can also happen independently of allergies. The lung’s lining cells release their own signals that ramp up IL-5 production through a separate pathway, which is why some people develop eosinophilic asthma without any allergic history at all.
How It’s Identified
Doctors typically use a blood test to check eosinophil levels. A count above 300 cells per microliter of blood is the widely used cutoff for identifying the eosinophilic subtype. This threshold helps predict both the risk of flare-ups and the likelihood of responding well to targeted treatments. A lower threshold of 150 cells per microliter is sometimes used when evaluating whether a patient might benefit from biologic medications.
The gold standard for confirming eosinophilic airway inflammation is a sputum test, where a sample of mucus from the lungs is analyzed. If eosinophils make up 2% or more of the cells in the sample, that confirms the diagnosis. However, sputum testing is less practical than a blood draw and shows inconsistent results between visits, so blood eosinophil counts remain the more common diagnostic tool in clinical practice.
Who Develops It
Eosinophilic asthma often looks different from the childhood allergic asthma most people picture. While classic asthma typically starts in childhood, is tied to allergies, and is more common in females, the eosinophilic subtype frequently begins in adulthood. People who develop it as adults tend to be older at the time of diagnosis and often have milder, less typical respiratory symptoms at first, which can delay recognition.
This adult-onset pattern is one reason it can fly under the radar. Someone who never had asthma as a child may not immediately connect persistent coughing, shortness of breath, or frequent respiratory infections to an asthma diagnosis, let alone a specific subtype of it.
Common Overlapping Conditions
Eosinophilic asthma frequently comes with nasal polyps, which are noncancerous growths in the sinuses. In studies of people with severe eosinophilic asthma, about 19% had nasal polyps at baseline. This overlap matters because nasal polyps can worsen sinus congestion, reduce the sense of smell, and contribute to chronic sinus infections, all of which compound the burden of the asthma itself. The same eosinophil-driven inflammation responsible for the lung symptoms also fuels polyp growth in the sinuses.
Why the Subtype Matters for Treatment
Identifying eosinophilic asthma isn’t just an academic exercise. It determines which treatments will actually work. Standard asthma inhalers and oral steroids may help temporarily, but people with this subtype often experience frequent flare-ups despite being on those medications. The exacerbation-prone pattern, defined as more than three flare-ups per year, is closely linked to eosinophilic inflammation.
Three biologic medications targeting the IL-5 pathway are now FDA-approved specifically for severe eosinophilic asthma. Two of them block IL-5 directly, preventing it from activating eosinophils. The third blocks the receptor that IL-5 binds to on the eosinophil surface. All three are given as injections, either monthly or every eight weeks depending on the medication, and are used as add-on therapy for people whose asthma isn’t controlled by standard treatments. In clinical trials, these biologics reduced flare-ups, improved lung function, and in some cases allowed patients to lower their steroid doses.
By contrast, people with non-eosinophilic asthma subtypes, such as neutrophilic or paucigranulocytic asthma, have far fewer targeted treatment options. The availability of effective biologics for the eosinophilic subtype is actually one of its relative advantages, making proper identification all the more important.
The Bottom Line on Rarity
Eosinophilic asthma is not rare by any medical or regulatory definition. It is, however, frequently underdiagnosed because it requires specific blood or sputum testing that not every asthma patient receives. If you have asthma that started in adulthood, responds poorly to standard inhalers, or comes with frequent flare-ups and sinus problems, eosinophil testing can clarify whether this subtype is driving your symptoms and open the door to more targeted treatment options.